Step 1: Understanding the Concept:
Reversal of $lpha_2$-adrenoceptor agonist sedative-analgesics using competitive competitive central $lpha_2$-antagonists.
Step 2: Detailed Explanation:
Pharmacology of $\alpha_2$-adrenergic reversal agents:
- Xylazine Hydrochloride is a potent, selective $\alpha_2$-adrenoceptor agonist widely used in veterinary anesthesia for sedation, muscle relaxation, and analgesia (adverse effects include bradycardia, hypotension, respiratory depression, rumen stasis, and bloat).
- Its sedative and toxic depressant effects are rapidly and specifically reversed by competitive selective $\alpha_2$-adrenoceptor antagonists, primarily Yohimbine Hydrochloride (D) (dose: $0.125\text{ mg/kg}$ i/v in cattle, $0.1\text{ mg/kg}$ in dogs) or Atipamezole Tolazoline.
- (Neostigmine reverses neuromuscular blockers; Atropine reverses muscarinic anticholinesterase toxicity).
Step 3: Final Answer:
Hence, the adverse effects of xylazine are reversed by D only, matching option (D).